|
|
Helmuth van Es (PhD) is member of the Advisory Board of Spinnovation.
Helmuth is a life sciences entrepreneur and renowned strategic thinker. He is co-founder of Galapagos (1998) a global drug discovery company where he was Head of Science until 2006. He was CSO of the EU site of stem cell based drug discovery company, SCI (2006-2007). He co-founded Audion Therapeutics in 2008 a company developing small molecule drugs to treat hearing loss. In 2009 Effecta Pharma was founded, a company focussing on solutions for bioavailability problems of small molecule drugs. He is non-executive Chairman of the supervisary board of Antabio, a company discovering and developing novel antibacterial therapeutics based on anti-virulence. He is owner of BioConsilium, a successful strategic consultancy company that works with a wide variety of young and established life sciences companies in Europe (www.bioconsilium.com).
|
|
|
Paul Edwards (Ph.D, MBA), is a member of the Advisory Board of Spinnovation.
Paul has over 15 years of experience working within the Pharmaceutical and Biotechnology industry and is an internationally respected scientist with more than 50 peer-reviewed publications and patents. Currently he is Vice President of Chemistry for Boehringer Ingelheim (Canada) Ltd. and is based in Laval, Quebec. Before taking up this role at Boehringer Ingelheim in January 2007, he held a number of positions in the Pharmaceutical and Biotechnology industry. He was formally Director and Head of Chemistry for the biotechnology company Galapagos, based in Mechelen, Belgium. Prior to this he was Director of Medicinal Chemistry for Santhera Pharmaceuticals (previously Graffinity) based in Heidelberg, Germany. Before this he spent nearly seven year at Pfizer Global Research & Development based in Sandwich, Kent in the United Kingdom. Here he held various positions in the Medicinal Chemistry and Lead Discovery Technologies Departments. His first industrial employment came at Oxford Asymmetry International Ltd., (now Evotec), based in Abingdon, Oxfordshire in the United Kingdom. Prior to taking up tenure in industry, he was firstly a SmithKline Beecham postdoctoral fellow with Regents’ Professor Paul G. Gassman at the University of Minnesota, U.S.A, and then a postdoctoral fellow with Professor Steven V. Ley, FRS at the University of Cambridge in the United Kingdom.
In 1989 Paul was awarded a B.Sc honours degree in Chemistry, followed in 1992 by a Ph.D degree in organic chemistry, both from the University of Leicester in the United Kingdom. In 2005 Paul received an MBA degree from the Open University in the United Kingdom.
Paul is a Fellow of the Chartered Management Institute (FCMI) and a Chartered Manager (CMgr), he is a Chartered Chemist and Fellow of the Royal Society of Chemistry (C.Chem., FRSC), a Chartered Scientist (C.Sci.), and a European Chemist (EurChem.).
|
|
|
Maarten Honing (PhD), is member of the Advisory Board of Spinnovation.
After a PhD within the field of analytical mass spectrometry at the Free University (Amsterdam, Netherlands) and Consejo Superior (Barcelona, Spain) and a one year Postdoc, Maarten joined the CRO Pharma Bio-Research as Head of the LC-MS/MS laboratory and Analytical Project Manager for Phase I/ II clinical trials. Within this two year period, he was responsible for the development, full validation and application of LC-MS/MS assays for e.g. GSK (paroxitine, rinanvir), Synthelabo (diltiazem), Pierre Fabre (idaxozan) en Elan coorperation (morphine en metabolites), project manager clinical chemistry voor Paraxel and immunoassays voor Ferring AG. Then he moved to Organon (now Merck Sharp & Dohme) where he held various management positions within the preclinical development and drug discovery units over the past 14 years.
In 2004 he moved to Organon's drug discovery unit and became head of the analytical sciences section within the medicinal chemistry department. During this period he also held several additional managing responsibilities such as chairman of the ‘pharmaceutical analytical laboratory managers" (PALM) group, coordinator of analytical sciences within discovery (reporting to the Vice President Research) and setting up an analytical network and collaborations with academia and research consortia.
|
|
